Additionally, an earlier trial involving anti-VEGF agents found that patients with wet age-related macular degeneration treated with bevacizumab experienced more significant systemic toxicity than those treated with ranibizumab [78]. This evidence concerns the gene VEGFA and wet macular degeneration.